Howard Hertz
Internal Medicine · Babylon, NYNPI 1942350780
Payments from drug & device makers
Across 113 payments — averaging $27.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intra-sana Laboratories$282
- Biotronik Inc.$264
- Abbott$251
- Exact Sciences$240
- Welch Allyn$176
- Bayer$168
- plus $2K from 30 others
What the payments were for
- Food & beverage$2,87392%
- Other$2648%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intra-sana Laboratories | 3 | $282 |
| Biotronik Inc. | 4 | $264 |
| Abbott | 13 | $251 |
| Exact Sciences | 12 | $240 |
| Welch Allyn | 1 | $176 |
| Bayer | 7 | $168 |
| Medtronic | 6 | $145 |
| AbbVie | 6 | $139 |
| Watermark Medical, Inc. | 1 | $126 |
| Amgen(2 entities) | 4 | $100 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $97 |
| Pfizer | 5 | $96 |
| Baxter Healthcare | 1 | $88 |
| Novartis | 4 | $83 |
| Lilly USA, LLC | 4 | $78 |
| Merck | 4 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $63 |
| Novo Nordisk | 3 | $60 |
| Johnson & Johnson | 4 | $59 |
| RGH Enterprises LLC | 2 | $51 |
| Sumitomo Pharma America, Inc. | 2 | $50 |
| Heartflow, Inc. | 2 | $40 |
| Atricure, Inc. | 1 | $38 |
| AstraZeneca | 2 | $38 |
| Nalpropion Pharmaceuticals LLC | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Global Blood Therapeutics, Inc. | 2 | $35 |
| GSK | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Bioxcel Therapeutics, Inc. | 1 | $29 |
| Sanofi | 1 | $27 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reltone 200 Mg$255
- GLYCATE$255
- Reltone 400 Mg$255
- NONE$176
- ARES HOME SLEEP TESTING DEVICE$126
How this compares
$3,137 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 185 | $231,465 |
| EliquisApixaban | 63 | $87,567 |
| JardianceEmpagliflozin | 54 | $78,822 |
| FarxigaDapagliflozin Propanediol | 53 | $77,792 |
| MounjaroTirzepatide | 51 | $73,669 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $59,572 |
| JanuviaSitagliptin Phosphate | 28 | $40,602 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $36,041 |
| EntrestoSacubitril/Valsartan | 20 | $34,157 |
| JanumetSitagliptin Phos/Metformin Hcl | 31 | $33,780 |
| RybelsusSemaglutide | 19 | $33,025 |
| XareltoRivaroxaban | 20 | $30,980 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $22,969 |
| LinzessLinaclotide | 12 | $17,653 |
| Bydureon BciseExenatide Microspheres | 15 | $15,066 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $60 | $264,490204 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $38 | $92,76367 claims |
| PfizerEliquis | $96 | $87,56763 claims |
| Boehringer IngelheimJardiance, Jentadueto | $13 | $85,90366 claims |
| MerckJanuvia, Janumet | $76 | $74,38259 claims |
| Lilly USA, LLCMounjaro | $78 | $73,66951 claims |
| GSKTrelegy Ellipta | $33 | $59,57257 claims |
| NovartisEntresto | $83 | $34,15720 claims |
| Johnson & JohnsonXarelto | $59 | $30,98020 claims |
| AbbVieLinzess, Synthroid | $139 | $20,92864 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Babylon
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.